New research suggests that people who stop taking weight loss injections may face a higher risk of heart attack, stroke and death. The findings come from a study of more than 80,000 people with type 2 diabetes in Italy.
Study findings on stopping GLP-1 treatment
Researchers analysed medical records from 301 diabetes clinics in Italy, covering the years 2004 to 2024. None of the patients had established cardiovascular disease at the start of the study. The research was published in The Lancet Regional Health - Europe in November 2026.
The study compared people who stopped taking GLP-1 medication with those who continued. Those who continued used the drugs for nearly three years on average, while those who stopped did so for just over a year.
Risk roughly twice as high after stopping
The combined rate of non-fatal heart attack, non-fatal stroke or death from any cause was approximately twice as high among those who discontinued treatment. The association appeared more pronounced among people who remained obese after stopping.
Researchers noted that the elevated risk was not entirely explained by changes in weight, blood sugar or blood pressure. However, the study did not determine why people stopped taking the medication, which was a significant limitation.
Interpreting the results
Dr Francesco Lo Monaco, cardiologist and founder of the National Longevity Clinic, said the results highlight the importance of understanding the potential cardiovascular consequences of discontinuing treatment.
He said: "GLP-1 medicines are increasingly being used to manage type 2 diabetes and obesity, and we know that these conditions are closely linked to cardiovascular health. These findings are interesting because they suggest that the potential benefits of treatment may extend beyond weight loss and blood sugar control. But we need to be very careful about interpreting them."
Dr Lo Monaco added: "This was an observational study. It cannot prove that stopping the medication caused the higher risk. People may have stopped treatment because they were already becoming unwell, or for other reasons that also affected their health."
Advice for patients considering stopping
The research does not suggest that everyone taking a GLP-1 medication must continue it for life. There may be legitimate clinical reasons to stop or change treatment, including side effects, changes in health, or a decision made with a healthcare professional.
Dr Lo Monaco said: "People should not stop prescribed medication or make changes to their treatment without speaking to their treating clinician first. The right approach will depend on the individual - their medical history, their risk factors and why they are taking the medication in the first place.
"What this research highlights is the importance of having a plan for treatment, including what happens if a patient needs to stop. It is not evidence that everyone needs to remain on these drugs indefinitely."
The researchers noted that further investigations are required to establish whether discontinuing GLP-1 treatment directly impacts cardiovascular risk, or whether the association reflects underlying differences in the health of those who cease treatment.